Oncolytics Biotech Inc. (ONCY)

Market Cap	108.68M
Revenue (ttm)	n/a
Net Income (ttm)	-25.32M
Shares Out	107.61M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,907,178
Open	1.000
Previous Close	0.973
Day's Range	1.000 - 1.080
52-Week Range	0.326 - 1.510
Beta	0.98
Analysts	Strong Buy
Price Target	6.00 (+494.06%)
Earnings Date	Mar 6, 2026

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 1999
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCY
• Website: https://oncolyticsbiotech.com

Financial Performance

Financial numbers in CAD

Analyst Summary

According to 6 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 494.06% from the latest price.

Price Target

$6.0

(494.06% upside)

Analyst Consensus: Strong Buy